Valeo Pharma Inc.
VPHIF · OTC
10/31/2023 | 10/31/2022 | 10/31/2021 | 10/31/2020 | |
|---|---|---|---|---|
| Revenue | $54 | $28 | $14 | $7 |
| % Growth | 94.3% | 104.7% | 81.5% | – |
| Cost of Goods Sold | $41 | $21 | $10 | $6 |
| Gross Profit | $13 | $6 | $4 | $1 |
| % Margin | 24.3% | 22.6% | 29.2% | 18.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $23 | $19 | $13 | $3 |
| SG&A Expenses | $29 | $25 | $16 | $5 |
| Sales & Mktg Exp. | $7 | $6 | $3 | $2 |
| Other Operating Expenses | $1 | $3 | $0 | $0 |
| Operating Expenses | $30 | $28 | $17 | $6 |
| Operating Income | -$17 | -$20 | -$13 | -$4 |
| % Margin | -32% | -70.7% | -94.5% | -58.1% |
| Other Income/Exp. Net | -$11 | -$7 | -$1 | -$0 |
| Pre-Tax Income | -$28 | -$27 | -$14 | -$5 |
| Tax Expense | $0 | -$1 | $0 | $0 |
| Net Income | -$28 | -$26 | -$14 | -$5 |
| % Margin | -51.6% | -92.8% | -105% | -63.7% |
| EPS | -0.32 | -0.32 | -0.2 | -0.082 |
| % Growth | 0% | -60% | -143.3% | – |
| EPS Diluted | -0.32 | -0.32 | -0.2 | -0.082 |
| Weighted Avg Shares Out | 86 | 81 | 70 | 58 |
| Weighted Avg Shares Out Dil | 86 | 81 | 70 | 58 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $0 | $0 | $0 |
| Interest Expense | $14 | $6 | $1 | $1 |
| Depreciation & Amortization | $3 | $1 | $0 | $0 |
| EBITDA | -$11 | -$16 | -$11 | -$4 |
| % Margin | -21.1% | -58% | -81% | -50.1% |